ONL Therapeutics Completes Enrollment in Global Phase 2 Trial for Geographic Atrophy Treatment
Rapid Read

ONL Therapeutics Completes Enrollment in Global Phase 2 Trial for Geographic Atrophy Treatment

What's Happening? ONL Therapeutics, a clinical-stage biopharmaceutical company, has announced the completion of enrollment for its global Phase 2 GALAXY trial. The trial, which is evaluating the efficacy and safety of xelafaslatide (formerly ONL1204) for patients with geographic atrophy (GA) associa
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.